Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 apr 2016 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma announces Annual Results for the year ended 31 December 2015
Bericht
Amsterdam, The Netherlands, April 15, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its audited annual results for the year ended 31 December 2015, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.
Operating highlights (including post the period end)
• Strong progress was made in developing lead product ATIR101™ for blood cancer:
o full enrolment of the single dose Phase II clinical trial was completed;
o positive data was presented at the American Society of Hematology (ASH) Annual Meeting in December 2015;
o positive results on the primary endpoint were presented at the Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT) in April 2016;
o a further repeat-dosing Phase II clinical trial with ATIR101™ commenced patient enrolment in October 2015;
o a closed manufacturing process for ATIR101™ was established which allows for automation;
o preparations to initiate a randomised Phase III trial with ATIR101™ in the second half of 2016 are underway;
o ATIR101™ was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the European Medicinal Agency (EMA).
• Entered into a partnership with the U.S. Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer in early 2016.
• Signed a collaboration with the Thalassaemia International Federation (TIF), an internationally renowned organisation that seeks to address the needs of patients, carers, healthcare professionals and the general public in the area of thalassaemia for ATIR201™ in inherited blood disorders.
Financial highlights
• Shares listed via an initial public offering (IPO) on Euronext Amsterdam a
Datum laatste update: 30 december 2025